Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase 2, Factorial-Designed, Randomized, Double-Blind, Placebo-Controlled, Parallel- Cohort Study to Evaluate Efficacy and Safety of MELT-300 and the Contribution of Midazolam and Ketamine Components to Sedation and Intraoperative Ocular Analgesia in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

To see complete record on, please visit this link

Id: NCT05133518

Organisation Name: Melt Pharmaceuticals

Overal Status: Recruiting

Start Date: July 20, 2021

Last Update: August 25, 2022

Lead Sponsor: Melt Pharmaceuticals

Brief Summary: The primary purpose of the study is to evaluate the efficacy and safety of MELT-300 (Midazolam and Ketamine Sublingual Tablets) and the contribution of midazolam and ketamine components to sedation and during the surgery or ocular analgesia in participants undergoing cataract surgery with lens replacement.

  • Cataract

Total execution time in seconds: 0.52245306968689